Escitalopram
Cognitive Disorder
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Axis
Score How the asset performs on this axis, from 0 to 100. Colour flags strength: green is strong, amber is mixed, red is weak.
Influence How much this axis matters relative to the strongest axis on this page. Hover for the underlying methodology share.
Clinical EvidenceClinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60
ConfUnderlying methodology share. Confidence: three dots confirmed, two provisional, one indicative.
Competitive PositionCompetitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73
ConfUnderlying methodology share. Confidence: three dots confirmed, two provisional, one indicative.
Scientific Foundation
NR
Conf
Development Feasibility
NR
Conf
Commercial Opportunity
NR
Conf
IP & Exclusivity
NR
Conf
Manufacturing & Supply
NR
Conf